Breaking News, Financial News

Financial Report: Gilead

Sovaldi sales drive triple-digit growth in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead 2Q Revenues: $6.5 billion (+136%) 2Q Earnings: $3.7 billion (+375%) YTD Revenues: $11.5 billion (+118%) YTD Earnings: $5.9 billion (+295%) Comments: Antiviral product sales increased to $6.0 billion in the quarter driven by sales of Sovaldi, which launched in December 2013. Complera/Eviplera sales were $299.5 million, up 59%, and Stribild sales were $269.5 million, up 171%. Atripla sales declined 7% to $870.7 million and Truvada sales were flat in the quarter. Cardiovascular product ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters